share_log

Arcutis Biotherapeutics | 424B5: Prospectus

SEC announcement ·  Mar 1 16:16
Summary by Moomoo AI
Arcutis Biotherapeutics, a commercial-stage biopharmaceutical company, has announced the offering of 15,789,474 shares of its common stock. The shares are listed on the Nasdaq Global Select Market under the symbol 'ARQT.' The offering price per share is set at $9.50, aiming to raise approximately $150 million before expenses. Underwriters have been granted a 30-day option to purchase up to an additional 2,368,421 shares. The offering is expected to close on or about March 4, 2024. Morgan Stanley, TD Cowen, Guggenheim Securities, Mizuho, and Needham & Company are managing the offering. The proceeds are intended for funding the continued commercialization, development, and approval of Arcutis' multiple programs, including potential launches in atopic dermatitis and scalp psoriasis, and for general corporate purposes.
Arcutis Biotherapeutics, a commercial-stage biopharmaceutical company, has announced the offering of 15,789,474 shares of its common stock. The shares are listed on the Nasdaq Global Select Market under the symbol 'ARQT.' The offering price per share is set at $9.50, aiming to raise approximately $150 million before expenses. Underwriters have been granted a 30-day option to purchase up to an additional 2,368,421 shares. The offering is expected to close on or about March 4, 2024. Morgan Stanley, TD Cowen, Guggenheim Securities, Mizuho, and Needham & Company are managing the offering. The proceeds are intended for funding the continued commercialization, development, and approval of Arcutis' multiple programs, including potential launches in atopic dermatitis and scalp psoriasis, and for general corporate purposes.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more